ADVANCED PHARMACOLOGY PRACTICE TEST
ACTUAL EXAM WITH 67 Q&A
LATEST 2026
RATED A+
WITH INSTANT PDF DOWNLOAD
NURSE CELESTINE
,1. Explain the significance of ATP Citrate Lyase (ACL) inhibition in the context of lipid
management and how it differs from the action of HMG-CoA reductase inhibitors.
It reduces cholesterol absorption in the intestines.
It decreases the synthesis of cholesterol by acting earlier in the mevalonate
pathway.
It increases HDL levels in the blood.
It directly inhibits the production of triglycerides.
2. Explain the role of Antithrombin in the coagulation process. How does it contribute to
maintaining hemostasis?
It activates coagulation factors
It inhibits thrombin and factor Xa
It promotes platelet aggregation
It increases blood clot formation
3. Explain why ezetimibe is considered a suitable next step for patients who do not
achieve LDL goals with statins alone.
Ezetimibe works by increasing the absorption of cholesterol in the intestines.
Ezetimibe has a synergistic effect when combined with statins, enhancing
LDL reduction.
Ezetimibe is primarily used for managing triglycerides.
Ezetimibe is only effective in patients who cannot tolerate statins.
4. A patient has permanent atrial fibrillation and a minor ischaemic stroke in the
anamnesis, and receives warfarin to prevent stroke. What is the target INR value?
3-4.5
, 2-3
1-2
1.5-2.5
5. (Question ID: 357) A physician decides to place a patient on a calcium channel
blocker for treatment of her angina. Calcium channel blockers can relax the smooth
muscle of blood vessels and can also have various effects on cardiac contractility,
conduction, and heart rate. Which of the following calcium channel blockers would
be most effective in reducing heart rate and contractility?
Dihydropyridine
Diltiazem
Nifedipine
Nimodipine
Verapamil
6. You are designing a pharmacotherapy regimen to include dyslipidemia management
for a patient that is already taking a maximally tolerated dosage of a statin. This
patient needs additional reduction of LDL cholesterol. Since the patient has a
documented statin intolerance, you decide to start the patient on Bempedoic Acid
(Nexletol) for additional LDL reduction given evidence from the Bempedoic Acid and
CV Outcomes Trial. Which of the following best describes the mechanism of action of
this medication?
HMG CoA Reductase Inhibitor
NPC1L1 Inhibitor
Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor
PCSK9 mAb
7. Which of the following agents is used in the treatment of HIT?
unfractionated heparin
argatroban
ACTUAL EXAM WITH 67 Q&A
LATEST 2026
RATED A+
WITH INSTANT PDF DOWNLOAD
NURSE CELESTINE
,1. Explain the significance of ATP Citrate Lyase (ACL) inhibition in the context of lipid
management and how it differs from the action of HMG-CoA reductase inhibitors.
It reduces cholesterol absorption in the intestines.
It decreases the synthesis of cholesterol by acting earlier in the mevalonate
pathway.
It increases HDL levels in the blood.
It directly inhibits the production of triglycerides.
2. Explain the role of Antithrombin in the coagulation process. How does it contribute to
maintaining hemostasis?
It activates coagulation factors
It inhibits thrombin and factor Xa
It promotes platelet aggregation
It increases blood clot formation
3. Explain why ezetimibe is considered a suitable next step for patients who do not
achieve LDL goals with statins alone.
Ezetimibe works by increasing the absorption of cholesterol in the intestines.
Ezetimibe has a synergistic effect when combined with statins, enhancing
LDL reduction.
Ezetimibe is primarily used for managing triglycerides.
Ezetimibe is only effective in patients who cannot tolerate statins.
4. A patient has permanent atrial fibrillation and a minor ischaemic stroke in the
anamnesis, and receives warfarin to prevent stroke. What is the target INR value?
3-4.5
, 2-3
1-2
1.5-2.5
5. (Question ID: 357) A physician decides to place a patient on a calcium channel
blocker for treatment of her angina. Calcium channel blockers can relax the smooth
muscle of blood vessels and can also have various effects on cardiac contractility,
conduction, and heart rate. Which of the following calcium channel blockers would
be most effective in reducing heart rate and contractility?
Dihydropyridine
Diltiazem
Nifedipine
Nimodipine
Verapamil
6. You are designing a pharmacotherapy regimen to include dyslipidemia management
for a patient that is already taking a maximally tolerated dosage of a statin. This
patient needs additional reduction of LDL cholesterol. Since the patient has a
documented statin intolerance, you decide to start the patient on Bempedoic Acid
(Nexletol) for additional LDL reduction given evidence from the Bempedoic Acid and
CV Outcomes Trial. Which of the following best describes the mechanism of action of
this medication?
HMG CoA Reductase Inhibitor
NPC1L1 Inhibitor
Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor
PCSK9 mAb
7. Which of the following agents is used in the treatment of HIT?
unfractionated heparin
argatroban
